COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

被引：0
|
作者：
Baker, T. [1 ]
Paly, V. F. [1 ]
Johnson, H. M. [2 ]
Van Campenhout, H. [3 ]
Amadi, A. [2 ]
Chandran, N. [4 ]
Moshyk, A. [5 ]
Kotapati, S. [5 ]
机构：
[1] ICON Plc, New York, NY USA
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Braine Lalleud, Belgium
[4] ICON Plc, Bangalore, Karnataka, India
[5] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN142
引用
收藏
页码：S462 / S463
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN: ANALYSIS USING 28-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
    Baker, T.
    Paly, V. F.
    Sabater, J.
    Holmberg, C.
    Hultberg, M.
    Lundstrom, J.
    Minacori, R.
    Chirita, O.
    VALUE IN HEALTH, 2017, 20 (09) : A444 - A444
  • [2] Cost-effectiveness of nivolumab plus ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067
    Sabater, J.
    Baker, T.
    Paly, V.
    Gupte-Singh, K.
    Lorenzi, M.
    Jeffers, A.
    Beyhaghi, H.
    Kotapati, S.
    Rao, S.
    Briggs, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN THREE EUROPEAN COUNTRIES USING 28-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
    Hirst, A.
    Paly, V. F.
    Diamantogiannis, F.
    Guilmet, C.
    Polanco, S. C.
    Sabater, J.
    Chirita, O.
    VALUE IN HEALTH, 2017, 20 (09) : A432 - A432
  • [4] COST-EFFECTIVENESS OF NIVOLUMAB (NIVO) AND NIVO IN COMBINATION WITH IPILIMUMAB (IPI) IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN COLOMBIA: ANALYSIS USING 78-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
    Kendall, R.
    Barco, V
    Sharma, A.
    McDonald, L.
    Perlaza, Garcia J.
    Baker, T.
    VALUE IN HEALTH, 2023, 26 (12) : S187 - S187
  • [5] COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN SWEDEN
    Baker, T. M.
    Paly, V. F.
    Thybo, S.
    Hultberg, M.
    Minacori, R.
    Kotapati, S.
    Sabater, J.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A731
  • [6] COST-EFFECTIVENESS OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) COMPARED WITH NIVO AND IPI MONOTHERAPIES IN THE FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN THE UNITED STATES: ANALYSIS USING 28-MONTH OVERALL SURVIVAL (OS) DATA FROM CHECKMATE 067
    Baker, T.
    Paly, V. F.
    Sabater, J.
    Gupte-Singh, K.
    Beyhaghi, H.
    Kotapati, S.
    Rao, S.
    Briggs, A.
    VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
  • [7] Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
    Timothy Baker
    Helen Johnson
    Srividya Kotapati
    Andriy Moshyk
    Melissa Hamilton
    Murat Kurt
    Victoria Federico Paly
    PharmacoEconomics - Open, 2022, 6 : 697 - 710
  • [8] Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
    Baker, Timothy
    Johnson, Helen
    Kotapati, Srividya
    Moshyk, Andriy
    Hamilton, Melissa
    Kurt, Murat
    Paly, Victoria Federico
    PHARMACOECONOMICS-OPEN, 2022, 6 (05) : 697 - 710
  • [9] First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma
    Turajlic, S.
    Gore, M.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 542 - 543
  • [10] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST -LINE TREATMENT OF ADVANCED MELANOMA
    Baker, T. M.
    Paly, V. F.
    Sabater, J.
    Okoro, T.
    Kotapati, S.
    Briggs, A.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
12345